New GPCR structures: SMO, 5-HT1B, 5-HT2B
Since the last GPCR structure post of jpo, three novel GPCR receptors have had their structure solved.
1) 5-hydroxytryptamine receptor 1B, 5-HT1B, in complex with the agonist Ergotamine(4iaq) (1)
2) 5-hydroxytryptamine receptor 1B, 5-HT2B, in complex with Dihydroergotamine and Ergotamine (4ib4, 4iar) (1)
3) The first class F receptor, the Smoothed Homolog (2), in complex with an agonizing anti-tumor agent, LY2940680 (4jkv)
The latter gave me quite a headache since its sequence identify with class A GPCRs is <10, and it is missing some of the very conserved motifs. Trying to align it with pure sequence alignment is next to impossible. Luckely I could make use of 3D-Coffee, heavily overweighting the pairwise structural alignment produced by TMalign and sap. Mind you, the alignment could probably be optimized manually, but it is quite encouraging to see an automated mechanism doing such a good job. Oh, did I mention, you'll be able to inspect all of these alignments yourself in the upcoming version of the GPCR SARfari?
1. 4iaq (red) - Human 5-hydroxytryptamine receptor 1B
2. 4ib4A (red) - Human 5-hydroxytryptamine receptor 2B
3. 4jkvA (orange) - Human Smoothened Homolog
4. 3vw7 (pink) - Human Proteinase-activated receptor 1
5. 1f88A (yellow) - Bos taurus Rhodopsin
6. 2rh1 (green) - Human Beta-2 adrenergic receptor
7. 4djhA (violet) - Human Kappa-type opioid receptor
8. 4ej4 (blue) - Mus musculus Delta-type opioid receptor
Despite being so structurally different, there is a good conservation in the 3D structure - See figure 1. The superimposing was done using mnyfit, a program jpo wrote (3) sometime back when he was still a young lad pursuing a PhD degree. Oh, and a(nother) small teaser, that screenshot comes from the updated version of the GPCR SARfari I'm working on, where you can interact with the superimposed structures, showing ligands, binding sites etc.
It seems the next major one will be the first class B, the Glucagon receptor. Hopefully this won't break my code and set back my work a few weeks.
(1) Chong Wang et al., Science 3 May 2013: 340 (6132), 610-614
(2) Chong Wang et al., Nature 16 May 2013: 497, 338–343
(3) Kenji Mizuguch et al., Protein Science Nov 1998: 7 (11), 2469-2471
Updated: Somehow the HTML didn't render properly.
1) 5-hydroxytryptamine receptor 1B, 5-HT1B, in complex with the agonist Ergotamine(4iaq) (1)
2) 5-hydroxytryptamine receptor 1B, 5-HT2B, in complex with Dihydroergotamine and Ergotamine (4ib4, 4iar) (1)
3) The first class F receptor, the Smoothed Homolog (2), in complex with an agonizing anti-tumor agent, LY2940680 (4jkv)
The latter gave me quite a headache since its sequence identify with class A GPCRs is <10, and it is missing some of the very conserved motifs. Trying to align it with pure sequence alignment is next to impossible. Luckely I could make use of 3D-Coffee, heavily overweighting the pairwise structural alignment produced by TMalign and sap. Mind you, the alignment could probably be optimized manually, but it is quite encouraging to see an automated mechanism doing such a good job. Oh, did I mention, you'll be able to inspect all of these alignments yourself in the upcoming version of the GPCR SARfari?
1. 4iaq (red) - Human 5-hydroxytryptamine receptor 1B
2. 4ib4A (red) - Human 5-hydroxytryptamine receptor 2B
3. 4jkvA (orange) - Human Smoothened Homolog
4. 3vw7 (pink) - Human Proteinase-activated receptor 1
5. 1f88A (yellow) - Bos taurus Rhodopsin
6. 2rh1 (green) - Human Beta-2 adrenergic receptor
7. 4djhA (violet) - Human Kappa-type opioid receptor
8. 4ej4 (blue) - Mus musculus Delta-type opioid receptor
Despite being so structurally different, there is a good conservation in the 3D structure - See figure 1. The superimposing was done using mnyfit, a program jpo wrote (3) sometime back when he was still a young lad pursuing a PhD degree. Oh, and a(nother) small teaser, that screenshot comes from the updated version of the GPCR SARfari I'm working on, where you can interact with the superimposed structures, showing ligands, binding sites etc.
It seems the next major one will be the first class B, the Glucagon receptor. Hopefully this won't break my code and set back my work a few weeks.
10 20 30 40 50 4iaq ( 38 ) y-iyQdsislpwkvllvmllal-i 4lb4A ( 48 ) ee-q-gnkl-hwAallilmv 4jkvA ( 190 ) sgqÇevPLvrTdnpkSwyedveGÇGI-qçqNpLFteaeHqdMhsyIaa-f 3vw7 ( 91 ) dasgYLtsswLtlfVPsvYtg-V 1f88A ( 1 ) mnGtegpnfyVPfsnktgvVrsPfea-pQyyLaepwqFsmlAayMfl-l 2rh1 ( 29 ) devwvvgmgivmsl-i 4djhA ( 55 ) spaipviitavysv-v 4ej4 ( 41 ) rsasslalaiaitalYsa-v aaaaaaaaaaaa a 60 70 80 90 100 4iaq ( 60 ) tlaTtlsNafViatVyrt-rkLhtpanyLiasLAvTDllVSilVMpi--- 4lb4A ( 65 ) iipTigGNtlVilAVsle-kkLqyatnyFlmsLAvADllVGlfVMpi--- 4jkvA ( 238 ) GavTglcTlfTlaTFvadwrnsnrypaVILfyVNaCffvgSiGWlaQfmd 3vw7 ( 113 ) fvvSlplNimaivvFilk-mkvkkPAVVyMlhLAtADvlFVsv-Lpf--- 1f88A ( 48 ) imlGfpiNflTlyVTvqH-kkLrtpLNyILlnLAvADlfMVfgGFtT--- 2rh1 ( 44 ) vlaIvfgNvlVitAIakf-erLqtvtnyFItsLAcADlvMGlaVVpf--- 4djhA ( 70 ) fvvGlvgNslVmfVIiry-tkmktaTniYIfNLAlADalVTtT-Mpf--- 4ej4 ( 60 ) cavGllgNvlvmfgIvry-tkLktATniYIfNLAlADalATst-Lpf--- aaaaaaaaaaaaaaaaa aaaaaaaaaaaaaaaaaa aaa 110 120 130 140 150 4iaq ( 106 ) ----------Stmytv-tg-rWtlgqvvÇdfWlssDItCCTASIwHLCvi 4lb4A ( 111 ) ----------aLltim-feamWplplvlÇpawLflDVlfSTASIwHLCaI 4jkvA ( 288 ) garreIVçRadgTMRl-gE-pTsnetlsÇviiFviVYyAlMAGvvWFvvL 3vw7 ( 158 ) ----------kisYyfsgS-dWqfgselÇrfVtAaFYcnMYASIlLMtvI 1f88A ( 94 ) ----------TlyTSl-hG-yFvfgptGÇnlEGffATLGGEIaLwSLvvL 2rh1 ( 90 ) ----------gaahil-mk-mWtfgnfwçefWTSiDVlCVTASIeTLcvI 4djhA ( 115 ) ----------qstvyl-mn-sWpfgdvlÇkiVlsiDyyNMfTSIfTLtmM 4ej4 ( 105 ) ----------qsakyl-me-tWpfgellÇkaVlSidYyNMFTSIfTLtmM aaaaaa aaaaaaaaaaaaaaaaaaaaaaaaa 160 170 180 190 200 4iaq ( 144 ) AldrywaitdaveysakrtpkraavmialvwvfSisISl-pPf-fw-r-- 4lb4A ( 150 ) svdryiaIkkpiqanqynsratAfikitvVwliSigiAi-pVpikg-i-- 4jkvA ( 336 ) TyAWHTsFkalgttyqpgk-t--syfhllTwslPfvlTv-aIlavaqVDG 3vw7 ( 197 ) SiDrflAVvypm-----rtlgrAsftClaiwalAiagVv-pLllke-Qti 1f88A ( 132 ) aieRyvvvckpmsn-frfgenhAimgvafTwvmAlaCAa-pPlvgwSr-- 2rh1 ( 128 ) AvdryfAItspfkyqSlltknkArviilmvwivSgltSflpIqmhwyr-a 4djhA ( 153 ) SvdRyiaVchpvkaldfrtplkAkiinicIwllSssvGi-sAivlG-Gtk 4ej4 ( 143 ) SvDRyiavchpvkaldfrtpakAklinicIwvlAsgvGv-pimvmA-vtq aaaaaaaaa aaaaaaaaaaaaaaaaaaa aaa 210 220 230 240 250 4iaq ( 189 ) ------qa------s-eÇvv---n--------tdhilytvySTvgAFyfP 4lb4A ( 196 ) ------et-np-nni-tÇvL---t-------kerFgdfMlfgSlaAFftP 4jkvA ( 384 ) -DsV---------SG-IÇF-----------VGYknyryRagfVlapIglV 3vw7 ( 245 ) qvpglg-------it-Tçhdvlset----LlegyyayyfsafSavfFfvp 1f88A ( 178 ) ------YI-PE-GMQCSÇGI---DY-YTpheetnNesFViyMfvvHfiiP 2rh1 ( 177 ) -thqe-AinÇyaeet-çÇdf---f---------TnqayaiasSivSFyvp 4djhA ( 201 ) vredv-------dvi-eÇsl---qFpd-ddyswwdlfmkicVfifAfviP 4ej4 ( 191 ) prdg---------av-vÇml---qf-p-spswywdtvtkicvflfAfvvP aaaaaaaaaa aaa 260 270 280 290 300 4iaq ( 221 ) tllLialygrIyvears--r--------------ilma----arerkaTk 4lb4A ( 230 ) laiMivtyfltihALqkk---a---------------q--tisneqrask 4jkvA ( 412 ) livGgyfLirGvmtlfsIksn----hpglLsekaa---skinetMlrLgi 3vw7 ( 283 ) liiStvCyvsIirclss--s-a------------------anrskksrAl 1f88A ( 216 ) livIffcygqLvftvkea---AaS-------------a-ttqkaekevTr 2rh1 ( 212 ) lviMvfvYsrVfqeakr--q--------------l--k--fclkeHkaLk 4djhA ( 239 ) vliIivcytlMilrlksv---r-lls--------g---rekdrnlrritr 4ej4 ( 226 ) iliitvcyglMllrlrsv---r-----------------ekdrslrriTr aaaaaaaaaaaaaa aaaaaaa 310 320 330 340 350 4iaq ( 315 ) tLgiIlgaF-ivCWlpFFiiSlvmpi------------------------ 4lb4A ( 325 ) vlgivFflF-llmWcpFFitNitLvl-çd--sç---------------nq 4jkvA ( 455 ) fGflAfgfv-liTfscHfyDffnQae-We--rSFrdyVlçqançeiknr- 3vw7 ( 313 ) fLSaaVfcIFiiCFgpTNvlLiaHYsfl-sht-------------st--t 1f88A ( 253 ) MViiMviaF-liCWlpYAgvAfyIft-hq--gs---------------d- 2rh1 ( 274 ) tlgiIMgtF-tlcWlpFFiVNivhvi-qd---n---------------l- 4djhA ( 275 ) LVlvVVavF-vvcWtpIHifilveal-gs--------------------- 4ej4 ( 262 ) MVlvVvgaF-vvCWapIHifVivwtl-vd--in-----------rrd-p- aaaaaaaaa aaaaaaaaaaaaaaaa 360 370 380 390 400 4iaq ( 347 ) --hlaifdffTwlGYlNSliNPiiYtmsnedFkqafhkli-rfk 4lb4A ( 356 ) ttlqmlLeifvWiGYvSSGvNPlvyTlfnktFrdAfgrYi-tcnyr 4jkvA ( 513 ) -PsllvEkiNLfAmFgtGiaMStwvwtkatlliwrr-------twc 3vw7 ( 347 ) eaAYfaYLlcvCvSSiSCciDplIyyyAssec 1f88A ( 283 ) -fgPifMtipAFfAKtSAvyNPviYimmnkqFrnCmvttl-ccgknpstt 2rh1 ( 303 ) -irkevyillNwiGYvNSgfNpliYc-rspdfriAfqell-c-------- 4djhA ( 307 ) -aalssyyfcIalGytNSslNPilYafldenFkrcfrdfcf--p 4ej4 ( 295 ) -lvvaalhlcialGYaNSslNpvlYaflDenfkrc aaaaaaaaaaaaaaaaaaaaaaa aaaaaaa 410 4iaq 4lb4A 4jkvA 3vw7 1f88A ( 337 ) vsktetsqvapa 2rh1 ( 342 ) ------l 4djhA 4ej4
(1) Chong Wang et al., Science 3 May 2013: 340 (6132), 610-614
(2) Chong Wang et al., Nature 16 May 2013: 497, 338–343
(3) Kenji Mizuguch et al., Protein Science Nov 1998: 7 (11), 2469-2471
Updated: Somehow the HTML didn't render properly.